Ocular Therapeutix (OCUL) Cash & Equivalents (2013 - 2026)

Ocular Therapeutix's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $666.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 90.66% year-over-year to $666.7 million; the TTM figure through Mar 2026 stood at $666.7 million (up 90.66% YoY), while the FY2025 annual figure was $737.1 million, up 87.98% from the prior year.
• Cash & Equivalents was $666.7 million for Q1 2026 at Ocular Therapeutix, down from $737.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $737.1 million in Q4 2025 to a low of $66.6 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $306.3 million across 5 years, with a median of $344.8 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 50.49% in 2023, then soared 590.16% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $102.3 million in 2022, then soared by 91.4% to $195.8 million in 2023, then jumped by 100.25% to $392.1 million in 2024, then surged by 87.98% to $737.1 million in 2025, then declined by 9.55% to $666.7 million in 2026.
• The last three Cash & Equivalents figures came in at $666.7 million (Q1 2026), $737.1 million (Q4 2025), and $344.8 million (Q3 2025), per Business Quant data.